Hbot denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for hbot are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Hyperbaric Oxygen Therapy as Duplicate Therapy — and Why You Can Appeal

Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen in a pressurized chamber to treat a range of recognized medical conditions. UnitedHealthcare may issue a duplicate-therapy denial when it identifies another wound-care, tissue-healing, or adjunctive treatment already active in your record and concludes that HBOT would address the same therapeutic goal without additive benefit.

This denial reason is often misapplied to HBOT. HBOT works through a distinct physiological mechanism — systemic hyperoxia and pressure-mediated tissue oxygenation — that is not replicated by topical wound care, antibiotics, surgical debridement, or other treatments that may be co-occurring. The fact that another treatment is also being used does not make HBOT duplicative if it addresses a separate or complementary mechanism.

## Your Federal Appeal Rights

• Internal appeal: ERISA §503 (employer-sponsored plans) or state insurance law requires a full-and-fair internal review. File within the timeframe on your denial notice — typically 180 days.
• External review: After internal remedies are exhausted, ACA §2719 provides access to an Independent Review Organization. File within approximately four months of final internal denial. Expedited review is available when your health is at serious risk.

## Concrete Appeal Steps

1. Request UHC's written denial and the specific coverage policy version cited. 2. Identify the therapy UHC considers to be duplicating HBOT and obtain clinical documentation showing they work through distinct mechanisms. 3. Have your treating physician or wound-care specialist write a letter explaining why HBOT is not duplicative — specifically addressing the mechanism, clinical indication, and the medical necessity of adding HBOT alongside current treatment. 4. Compile records showing inadequate response to current therapy alone. 5. File the internal appeal; escalate to external review if denied.

## Documentation to Gather

• Confirmed diagnosis for which HBOT is indicated (e.g., diabetic foot wound, refractory osteomyelitis, radiation injury — as applicable per your clinical situation)
• Records of current wound-care or other treatments: dates, modalities, clinical response, objective wound measurements
• Prescribing physician's letter distinguishing HBOT's mechanism and clinical necessity from co-occurring therapies
• Any relevant specialty-society guidance (e.g., Undersea and Hyperbaric Medical Society indications list) cited generically
• Documentation of wound or condition progression despite current treatment

## Criteria-Mapping Structure

For each element of UHC's duplicate-therapy criteria, provide a direct rebuttal: identify the allegedly duplicative therapy, explain its mechanism, then explain HBOT's distinct mechanism and the specific clinical need it addresses that is not met by the current regimen. Supporting this with objective clinical measurements (wound size trends, lab markers, imaging) is particularly persuasive.